Mersana Therapeutics Inc (NASDAQ: MRSN) on Monday, soared 4.56% from the previous trading day, before settling in for the closing price of $0.43. Within the past 52 weeks, MRSN’s price has moved between $0.40 and $4.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12314.39% over the past five years. The company achieved an average annual earnings per share of -29.24%. With a float of $85.81 million, this company’s outstanding shares have now reached $115.65 million.
Let’s look at the performance matrix of the company that is accounted for 102 employees. In terms of profitability, gross margin is 56.37%, operating margin of -144.52%, and the pretax margin is -169.82%.
Mersana Therapeutics Inc (MRSN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Mersana Therapeutics Inc is 31.15%, while institutional ownership is 54.62%. The most recent insider transaction that took place on Jan 16 ’25, was worth 2,061. In this transaction VP, Chief Accounting Officer of this company sold 3,554 shares at a rate of $0.58, taking the stock ownership to the 57,519 shares. Before that another transaction happened on Jan 16 ’25, when Company’s Director sold 8,637 for $0.58, making the entire transaction worth $5,009. This insider now owns 168,041 shares in total.
Mersana Therapeutics Inc (MRSN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -29.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.09% during the next five years compared to 2.74% growth over the previous five years of trading.
Mersana Therapeutics Inc (NASDAQ: MRSN) Trading Performance Indicators
Mersana Therapeutics Inc (MRSN) is currently performing well based on its current performance indicators. A quick ratio of 2.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Mersana Therapeutics Inc (MRSN)
Mersana Therapeutics Inc (NASDAQ: MRSN) saw its 5-day average volume 2.79 million, a negative change from its year-to-date volume of 6.03 million. As of the previous 9 days, the stock’s Stochastic %D was 21.32%. Additionally, its Average True Range was 0.05.
During the past 100 days, Mersana Therapeutics Inc’s (MRSN) raw stochastic average was set at 1.66%, which indicates a significant decrease from 26.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.25% in the past 14 days, which was lower than the 145.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5651, while its 200-day Moving Average is $1.5837. Nevertheless, the first resistance level for the watch stands at $0.4539 in the near term. At $0.4630, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4811. If the price goes on to break the first support level at $0.4267, it is likely to go to the next support level at $0.4086. The third support level lies at $0.3995 if the price breaches the second support level.
Mersana Therapeutics Inc (NASDAQ: MRSN) Key Stats
Market capitalization of the company is 55.44 million based on 124,631K outstanding shares. Right now, sales total 40,500 K and income totals -69,190 K. The company made 16,360 K in profit during its latest quarter, and -14,120 K in sales during its previous quarter.
